Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical stage biopharmaceutical company that utilizes a proprietary technology platform to discover and develop novel peptide-based drugs to transform existing treatment paradigms for patients with significant unmet medical needs. PTG-100 is an oral alpha-4-beta-7 integrin antagonist peptide  that was being developed for inflammatory bowel diseases (IBD). ... Read more

Stock Quote

PTGX (Common Stock)
$7.340.00 (0.00%)
Exchange :NASDAQ
Volume :0
Today's Open$0.00
Previous Close$7.34
Data as of June 19, 2018 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $7.34 with a 52 week high of $23.97 and a 52 week low of $5.50.

Recent Press Releases

June 18, 2018

Protagonist Announces Phase 1 and Pre-clinical Data on Hepcidin Mimetic PTG-300 Presented at European Hematology Association Annual Meeting read more

June 06, 2018

Protagonist Therapeutics to Present at the 2018 JMP Securities Life Sciences Conference read more

June 01, 2018

Protagonist Therapeutics Reports Granting of Inducement Award read more

Upcoming Events

Presentation

Download Documentation Investor Presentation
Data provided by Nasdaq. Minimum 15 minutes delayed.